<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199234</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-0011</org_study_id>
    <nct_id>NCT04199234</nct_id>
  </id_info>
  <brief_title>Tolerability of Encapsulated Iron</brief_title>
  <official_title>Tolerability of Encapsulated Iron Compared to a Conventional Iron Supplement Such as Fe Sulphate Regarding Gastrointestinal Side-effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-clinical trial in which the adverse effects of two different iron supplements are
      compared
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of symptoms</measure>
    <time_frame>This variable will measure the changes of gastrointestinal symptoms during the period of consumption, that is, for 14 days.]</time_frame>
    <description>It will be evaluated by analog visual scale:nausea, vomiting, heartburn, abdominal pain, diarrhoea, constipation, breathless, headache, metallic taste and gas/bloating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health status quantification</measure>
    <time_frame>This variable will measure changes in health status during the period of consumption, that is, for 14 days</time_frame>
    <description>It will be evaluated by analog visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantification of the deterioration of daily activities</measure>
    <time_frame>This variable will measure the changes that occur in activities of daily living during the period of consumption, that is, for 14 days.]</time_frame>
    <description>It will be evaluated by analog visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bowel movements</measure>
    <time_frame>This variable will measure changes in bowel movements during the period of consumption, that is, for 14 days</time_frame>
    <description>They will be measured using the bristol scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron profile</measure>
    <time_frame>This variable analyzes the change in the state of iron in blood twice. Before and after the consumption of the product under study, that is 14 days</time_frame>
    <description>Ferritin (mg / dl) and hemoglobin (g / 100) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples</measure>
    <time_frame>This variable analyzes the changes before the consumption of the product under study and after 14 days of consumption.]</time_frame>
    <description>Hematological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine samples</measure>
    <time_frame>This variable analyzes changes in urine after 14 days of consumption</time_frame>
    <description>basic urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>This variable analyzes changes before the consumption of the product under study and after 14 days of consumption</time_frame>
    <description>Blood pressure (mmhg) and heart rate (beats per minute) are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>This variable analyzes changes before the consumption of the product under study and after 14 days of consumption</time_frame>
    <description>Blood pressure (mmhg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometric measures</measure>
    <time_frame>This variable analyzes changes in weight after 14 days of consumption</time_frame>
    <description>weight (kilos)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>This variable analyzes changes before the consumption of the product under study and after 14 days of consumption</time_frame>
    <description>heart rate (beats per minute)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Supplement</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg Iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg Iron sulphate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>experimental product consumption</intervention_name>
    <description>Consumption of an encapsulated iron supplement, orally two hours before eating.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omparator product consumption. (Iron sulphate.</intervention_name>
    <description>Consumption of an encapsulated iron supplement, orally two hours before eating.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy premenopausal women (Age: 18-50)

          -  Non-anemic

          -  Normal Iron status: hemoglobin (&gt;12 g/dL)

          -  Normal BMI (20-25 kg/m²)

          -  Normal blood profile at screening:

             a) Complete blood count, platelets, Glucose, HbA1c, Electrolytes (Na, K, Cl), AST,
             ALT, bilirubin, y-GT), Creatinine, eGFR, blood urea nitrogen, uric acid, Total protein
             (albumin/ globulin)

          -  Subject is in good physical health as established by medical history, vital signs,
             physical examination and electrocardiogram (ECG)

          -  Normal urine profile at screening:

             a) pH, protein, glucose, nitrite, ketone, bilirubin, urobilinogen, red blood cells,
             leukocytes, creatinine, sediments, absence of bacteria

          -  Regular menstrual cycle (28 +/- 5)

          -  Willingness not to change dietary (no start/ change of diet) and general habits (quit
             smoking) during study duration

          -  C-reactive protein: &lt; 5mg/L.

        Exclusion Criteria:

          -  Previous participation in iron tolerability trials.

          -  Participation in a clinical research trial within 30 days prior to randomization

          -  Chronic medication (except oral contraceptives)

          -  Pregnancy or lactation

          -  Hb levels &lt; 12g/dL (women) (anemia)

          -  Reported chronic disease

          -  Infectious disease

          -  Alcohol or drug abuse

          -  Hyperlipidemia as defined by LDL &gt; 3.36 mmol/L (130 mg/dL) and/or triglycerides &gt; 2.26
             mmol/L (200 mg/dL).

          -  Relevant co-morbidities: Gastrointestinal disease such as peptic ulcer, enteritis, or
             ulcerative colitis, inflammation, pre-existing poorabsorption or liver disease, kidney
             disease, iron-storage disorders such as hemochromatosis, haemosiderosis, or chronic
             autoimmune inflammatory condition

          -  Serious illness that may confound study results or interfere with compliance

          -  Any other laboratory abnormality, medical condition or psychiatric disorder which in
             the Investigator's opinion may adversely affect the subject's ability to complete the
             study or its measures or which may pose significant risk to the subject

          -  Known intolerance to oral iron supplements

          -  Intake of iron suppl. and/or multivitamins containing iron during the last three
             months before study entry

          -  Use of any mineral/vitamin or other supplements during the past month prior to study

          -  Subject has a known allergy to the test material's active or inactive ingredients

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent

          -  Any active medical illness in last 48 h

          -  Sexually-active females who are not willing to use an effective form of birth control.

          -  Subjects with sever severe premenstrual symptoms (PMS)

          -  Subjects that have followed specific diet, eg. high protein diet, within 30 days prior
             to study start

          -  Previous gastric bypass, sleeve gastrectomy, or gastric band surgery

          -  Blood donation within the previous 1 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Javier López Roman</last_name>
    <phone>523</phone>
    <phone_ext>523</phone_ext>
    <email>jlroman@ucam.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fco Javier López Román</last_name>
      <phone>968278523</phone>
      <email>jlroman@ucam.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

